CompletedPhase 3NCT00179621
Lenalidomide Versus Placebo in Myelodysplastic Syndromes With a Deletion 5q[31] Abnormality
Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Celgene Corporation
- Principal Investigator
- Jay Backstrom, MDCelgene Corporation
- Intervention
- Lenalidomide 5 mg(drug)
- Enrollment
- 205 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2005 – 2010
Study locations (30)
- AZ St-Jan Brugge AV, Bruges, Belgium
- UZ Gent, Ghent, Belgium
- UZ Gasthuisberg, Leuven, Belgium
- CHU Mont Godine, Yvoir, Belgium
- Institut Paoli-Calmettes, Marseille, Cedex 9, France
- CHU d'Angers Service des Maladies du Sang, Angers, France
- Hopital Avicenne, Bobigny, France
- CHRU Lille Service des Maladies du Sang, Lille, France
- CHU Nantes Hematologie et Medicine interne, Nantes, France
- CHU Archet 1Hematologie Clinique, Nice, France
- Hôpital Cochin Hematologie Clinique, Paris, France
- Centre Jean Bernhard Service Onco-Hematologie, Poitiers, France
- Centre Henri Becquerel Service d'Hematologie Clinique, Rouen, France
- CHU Purpan, Place du Dr Baylac, Pavillon des Médecines, Toulouse, France
- CHU Purpan, Place du Dr. Baylac, Pavillion des Medecines, Toulouse, France
- +15 more locations on ClinicalTrials.gov
Collaborators
ICON Clinical Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00179621 on ClinicalTrials.govOther trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality
Additional recruiting or active studies for the same condition.